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Abstract: Asthma is a chronic inﬂammatory lung disease that results
in airﬂow limitation, hyperreactivity, and airway remodeling. There
is strong evidence that an imbalance between the reducing and
oxidizing systems favoring a more oxidative state is present in
asthma. Endogenous and exogenous reactive oxygen species, such as
superoxide anion, hydroxyl radical, hypohalite radical, and hydrogen
peroxide, and reactive nitrogen species, such as nitric oxide,
peroxynitrite, and nitrite, play a major role in the airway
inﬂammation and are determinants of asthma severity. Asthma is
also associated with decreased antioxidant defenses, such as
superoxide dismutase, catalase, and glutathione. In this review, we
will summarize the current knowledge and discuss the current and
future strategies for the modulation of oxidative stress in asthma.
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THE LINK BETWEEN INFLAMMATION OF
ASTHMA AND OXIDATIVE STRESS
Asthma is a chronic inﬂammatory lung disease involvingcomplex interactions between numerous cell types and
mediators that result in airway reactivity and airﬂow limita-
tion.1–5 There is strong evidence that the endogenous and
exogenous reactive oxygen and nitrogen species play a major
role in the airway inﬂammation and are determinants of
asthma severity1–6 (Fig. 1).
According to a recently proposed hierarchical oxidative
stress model,8,9 a low level of oxidative stress, such as expo-
sure to diesel exhaust products for 6 hours at a concentration
of 10 to 50 mg/mL,10 leads to the activation of the transcrip-
tion factor, nuclear erythroid 2 p45-related factor 2 (Nrf2),
which encodes more than 200 genes. These gene products
are responsible for a wide range of antioxidant, anti-
inﬂammatory, cytoprotective, and detoxiﬁcation functions
and include catalase, superoxide dismutase (SOD)-3,
heme oxygenase-1, glutathione-S-transferases, NAD(P)H-
quinone oxidoreductase (NQO1), glutathione peroxidase,
and glucuronosyltransferase-1a6 (UGT-1a6).11 At low level
of oxidative stress, antioxidants can restore cellular redox
homeostasis. When high levels of oxidative stimuli are pres-
ent, additional sets of intracellular signaling cascades are trig-
gered that are potentially proinﬂammatory. These include
mitogen-activated protein kinase and nuclear factor-kB
(NF-kB), which lead to the expression of inﬂammatory cyto-
kines, chemokines, and adhesion molecules. A further
increase in the level of oxidative stress could ultimately trig-
ger a cytotoxic response originating in the mitochondria and
lead to cellular apoptosis or necrosis (Fig. 2).
ENDOGENOUS PRODUCTION OF REACTIVE
OXYGEN SPECIES AND ITS BIOLOGICAL
EFFECTS IN ASTHMA
Inﬂammatory cells (such as activated eosinophils,
neutrophils, monocytes, and macrophages) and resident cells
(such as epithelial and smooth muscle cells) can generate
reactive oxygen species (ROS).12–14 Sources of O22 include
primarily nicotinamide adenine dinucleotide phosphate
(NADP) oxidase–dependent complex, the cytosolic xanthine
oxidase system, and the mitochondrial respiratory chain. O22
spontaneously or enzymatically dismutates to hydrogen per-
oxide (H2O2). Both O
2
2 and H2O2 interact with iron and other
metal ions and form OH- in biological systems.15–17 Eosino-
phils, neutrophils, and monocytes contain peroxidases that
catalyze the interaction between H2O2 and halides leading
to the formation of hypohalides, such as HOCl. In addition,
superoxide anion may also react with nitric oxide (NO) to
form peroxynitrite (ONOO-), a potent ROS.13–17
ROS can attack proteins to form carbonyls and react
with nitrogen species and tyrosine to form nitrotyrosine. In
murine and human studies, tyrosine nitration was shown to
increase after allergen exposure in sensitized mice or atopic
asthmatic humans.18 ROS also reacts with lipids to liberate
isoprostane and ethane.19–21 As a result, 8-isoprostane, a bio-
marker of lipid peroxidation, is elevated in the exhaled breath
condensate in adults and children with asthma.20 Similar to
the airways and systemic circulation, urinary levels of bromo-
tyrosine and F2-isoprostanes are elevated in patients with
asthma22 and are associated with an increased risk of having
asthma.
Excess production of ROS correlates with the degree of
airway hyperresponsiveness as quantiﬁed by methacholine
challenge.22–24 Asthma attacks and experimental antigen
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challenges are both associated with immediate formation of
O22 , being high at the sites of antigen challenge that persists
throughout the late asthmatic phase.22
The main nitrogen species produced in the lung is NO.
Autoxidation of NO with oxygen results in the formation of
nitrite, a substrate for eosinophil peroxidase (EPO) and
myeloperoxidase (MPO).25 Nitric oxide reacts with superox-
ide to form ONOO-, which can nitrate tyrosine residues and
thus damage enzymes, and structural and functional pro-
teins.13–15,25 Higher NO levels are associated with higher risk
of asthma, asthma severity, and greater response to broncho-
dilator agents.22,26
A link also exists between the increase in ROS and the
asthma severity. ROS production by neutrophils correlates with
the severity of the reactivity of airways.27 Increased levels of
EPO and MPO correlate with the numbers and activation of
eosinophils and neutrophils, respectively.28–30 The level of 3-
bromotyrosine, a unique product of EPO and eosinophils, was
found to be 3 times higher in the bronchoalveolar lavage (BAL)
ﬂuid of individuals with asthma compared with that in the
control subjects.31 In the intensive care unit, the level of
3-bromotyrosine in airways of severe asthma patients was
100-fold higher than that in individuals hospitalized for
nonasthma causes.32 MPO-mediated oxidation is also related
to asthma severity.30 Two to 3-fold elevations in chlorotyrosine
are detected from allergen-challenged subsegments in asthmatic
subjects.31 Similarly, children with asthma have increased lev-
els of malondialdehyde, a marker of lipid peroxidation, and
lower than normal levels of glutathione. Furthermore, the
higher levels of malondialdehyde correlated with the severity
of the asthma.33
EXPOSURE TO EXOGENOUS ROS AND ASTHMA
Respiratory system has a large surface area that is in
contact with the environment. Cigarette smoke, inhalation of
airborne pollutants (ozone, nitrogen dioxide, sulfur dioxide),
or particulate matter in the air can trigger symptoms of
asthma.34 Recently, a clear relationship between trafﬁc density
and asthma exacerbations was demonstrated.35 Ultraﬁne par-
ticles with a diameter of ,0.1 mm may directly induce mito-
chondrial damage and make it difﬁcult for the lungs to cope
with oxidative stress.36 Cigarette smoke is related to asthma
exacerbations, especially in young children, and there is
a dose-dependent relationship between exposure to cigarette
smoke and rates of asthma.37 Cigarette smoke is a highly
FIGURE 1. Asthma pathophysiology.
Adapted with permission from
Comhair and Erzurum.7
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complex mixture of more than 4000 chemical compounds
that are distributed in aqueous, gas, and the tar phase of the
smoke. In the gas phase, the smoke contains high concentra-
tions of O22 and nitric oxide. They immediately react to form
highly reactive peroxynitrite.38 The tar phase of the cigarette
smoke contains organic radicals that react with molecular ox-
ygen to form O22 , OH
-, and H2O2. The tar phase is an effective
metal chelator that chelates iron and generates H2O2 continu-
ously. Aqueous phase of the cigarette smoke may undergo
redox recycling for a period in the epithelial lining of the
lungs.39
IMBALANCE BETWEEN OXIDANTS AND ANTI-
OXIDANT SYSTEMS IN ASTHMA
Homeostasis of cellular functions during oxidative
stress depends on the appropriate induction of protective
antioxidant mechanisms. Antioxidants are major in vivo and
in situ defense mechanisms of the cells against oxidative
stress.9,13,15–17 Naturally occurring antioxidants work to pro-
tect cells and tissues against the continuous production of
reactive oxygen and reactive nitrogen species during normal
metabolism.40 Disequilibrium of the airway reducing state is
a determinant of asthma initiation and severity.1,4–6
The nonenzymatic antioxidants include ascorbic
acid, glutathione, albumin, a-tocopherol, uric acid, and
b-carotene.41–44 The major enzymatic antioxidants of the
lungs are SODs, catalase, and glutathione peroxidases as
well as heme oxygenase-1, thioredoxins, peroxiredoxins,
and glutaredoxins.41 Asthma is characterized by the loss of
antioxidant activities.7
We evaluated the enzymatic and nonenzymatic antiox-
idant systems in children with asthma.45 Levels of the enzymes
glutathione peroxidase and SOD and of the nonenzymatic
components of the antioxidant system including reduced glu-
tathione, ascorbic acid, a-tocopherol, lycopene, and b-carotene
were signiﬁcantly lower in children with asthma compared
with the healthy controls. In addition, of the amino acids con-
tributing to glutathione synthesis, glycine, and glutamine were
signiﬁcantly lower in children with asthma. The majority of the
amino acids susceptible to oxidative stress displayed lower
levels in children with asthma. The results of this study clearly
show that childhood asthma is associated with signiﬁcant
decreases in various components of both enzymatic and non-
enzymatic antioxidant defenses.45
Because superoxide is the primary ROS produced
from a variety of sources, its dismutation by SOD is of
primary importance for each cell. All 3 forms of SOD
(CuZn-SOD, Mn-SOD, and EC-SOD) are widely expressed
in the human lung.46,47 SOD activity is signiﬁcantly lower in
epithelial lining ﬂuid and airway epithelial cells in asthma
patients compared with that in the healthy controls.7 Studies
in large populations showed that the airway reactivity is
inversely related to SOD activity.5,48 Transgenic mice that
overexpress SOD had decreased allergen-induced physio-
logic changes in the airways compared with controls.49 It
seems that the lower SOD activity is partly a consequence of
the increased oxidative and nitrative stress in the asthmatic
airway and serves as a sensitive marker of airway redox and
asthma severity.7
In addition to lower SOD activity, CuZn-SOD protein
is decreased in asthmatic airway epithelium.50 Oxidation and
nitration of Mn-SOD are also present in the asthmatic airway,
correlating with the severity of the asthma.48,51 Overall, the
loss of SOD activity reﬂects oxidant stress in the airway.48
Catalase is a metalloprotein enzyme and the main
scavenger of H2O2. It is effective in high concentrations of
H2O2. Under prolonged oxidative stress, NADPH binds to
the enzyme and stabilizes the structure and protects catalase
from inactivation. This leads to the decrease in catalase activ-
ity.52 Both animal and human studies have shown that catalase
activity in BAL ﬂuid is lower in patients with asthma as com-
pared with that in healthy controls.53 The lower catalase activ-
ity is due to nitration and oxidation, which identiﬁes oxidative
inactivation as the mechanism of activity loss in vivo.53
Extracellular glutathione peroxidase is higher than
normal in the lungs of patients with asthma. Although ozone
decreased the levels of glutathione peroxidase protein and
activity, no change was detected with exposure to NO2.
6,54
During acute asthma exacerbations, glutathione levels in the
exhaled breath condensate of children were found to be lower
than those in the control subjects. In addition, the glutathione
levels in exhaled breath condensate increased after oral ste-
roid treatment compared with pretreatment levels.55 Glutathi-
one depletion leads to the inhibition of Th1-associated
cytokine production and favors Th2-associated response.56
In other words, reduction in glutathione levels supports the
maintenance of Th2 response in asthma.
GENES AND OXIDATIVE STRESS IN ASTHMA
Glutathione S-transferases (GST) include a number of
subclasses, such as GST-P1 and GST-M1, that are expressed
in the lungs and have been implicated in the pathogenesis of
asthma. Children with GSTM1 null or GSTP1 val/val geno-
types had increased respiratory symptoms upon exposure to
ozone.33,57,58 The same genotypes were associated with
higher nasal IgE and histamine response.59 Because these
FIGURE 2. The hierarchial oxidative stress model. Adapted
with permission from Riedl and Nel.9
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polymorphisms have a high frequency,60 they may have a sub-
stantial effect at the population level. GSTCD gene at 4q24
location was identiﬁed as one of the primary genes that
determine lung function.61
We genotyped patients with asthma and healthy indi-
viduals for null variants of GSTT1 and GSTM1 and ile105val
variant of GSTP1. Children with asthma possessing the GSTP1
val/val genotype had higher malondialdehyde and lower
glutathione levels compared with other genotypes in the
systemic circulation but not in the airways.33,62 This parti-
cular genotype was independently associated with the severity
of childhood asthma.
Similar genetic effects have been reported for SOD.
Ala16Val mutation in Mn-SOD changes the secondary
structure of the protein, which may affect the targeting of
the protein to mitochondria.63 The EC-SOD R213G polymor-
phism is associated with reduced exacerbations in chronic
obstructive pulmonary disease (COPD) and lower rates of
hospitalization.64 However, neither R213G (EC-SOD) nor
Ala16Val of Mn-SOD was associated with a genetic suscep-
tibility to develop asthma.63 This is an area that needs further
research (Fig. 3).
CLINICAL MONITORING OF OXIDATIVE STRESS
IN ASTHMA
Oxidants are produced at higher amounts either spon-
taneously or after the stimulation in patients with asthma
compared with healthy subjects. EPO and MPO are increased
in the peripheral blood, induced sputum, and BAL ﬂuid of
patients with asthma.65–68 Many direct or indirect markers of
oxidative stress, including malondialdehyde, thiobarbituric
acid, and glutathione disulﬁde, have been found in urine,
plasma, sputum, and BAL ﬂuid of patients with asthma,
and the level of the markers correlated with the severity of
the disease.67–69 Analysis of exhaled breath condensate has
allowed direct measurements of H2O2 and NO and the mea-
surement of several indirect by-products of oxidation like
isoprostane and ethane.20,21 Despite the difﬁculties to quan-
tify the ROS because of their labile nature, the stable end
products of the reactive pathways may be used as reliable
markers of oxidative stress in patients with asthma.7
One clinically useful biomarker of airway inﬂammation
is exhaled NO.7 During an asthma exacerbation and in the case
of uncontrolled asthma, the airway environment becomes more
acidic and oxidizing that leads to the release of NO from




Even though it is apparent that treatment modalities
targeting the oxidant stress has a great potential for the
treatment of many diseases including asthma, so far, human
studies have failed to reveal a clear beneﬁt.
Thiol Antioxidants
Thiol antioxidants that are metabolically converted to
glutathione precursors are popular alternatives as antioxidant
therapeutics. N-acetyl cysteine (NAC) is the most commonly
used thiol precursor. NAC was found to suppress airway in-
ﬂammation and hyperreactivity in animals70 and inhibit ROS
production in human peripheral blood eosinophils.71 In ani-
mal models, oral NAC exerted an antioxidant protective effect
and attenuated pulmonary inﬂammation.70,72
FIGURE 3. Genetic polymorphisms
lead to pathophysiological changes
that result in the inﬂammation of the
airways.
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In humans, according to meta-analyses, NAC is able to
decrease the exacerbation rate in patients with COPD by more
than 20%.73–75 However, in a controlled randomized study,
NAC was found to be ineffective in preventing the deteriora-
tion in lung function and exacerbations in patients with
COPD.76 In a recent study, NAC produced no signiﬁcant
beneﬁt when added to conventional treatment during an
asthma attack.77 The lack of clear beneﬁt in human studies
may be related to the relative instability of NAC.78,79
In addition to NAC, a more potent and orally available
thiol antioxidant is bucillamine. It stimulates the production
of precursors necessary for glutathione synthesis and induces
Nrf2 release into the nucleus. Thus, it might function as Nrf2
agonist.80 Bucillamine was shown to be safe in humans but
not tested yet for the reduction of oxidative stress in the
respiratory system of patients.81
Vitamins and Nutrients
The results of the studies evaluating the effects of
vitamins and nutrients on asthma have been controversial.82–88
In a murine study, it was shown that the administration of vita-
mins C and E caused decreases in ragweed extract–induced
ROS levels and is associated with lower airway allergic inﬂam-
mation.82 In an ovalbumin-sensitized rat model, 4 days of oral
treatment with g-tocopherol diminished eosinophil inﬁltration in
the nose, sinuses, and nasolacrimal duct but not in the lung after
allergen challenge.83
Even though epidemiological studies have suggested that
children with low dietary intake of vitamins and C E, and other
antioxidants have in general more symptoms,85,89 the results of
the clinical studies have been largely disappointing.86–88 Inter-
estingly, a recent study has even suggested that vitamin supple-
ments may increase the oxidant stress. In this study, the
investigators have hypothesized that the intake of antioxidant
vitamins would augment the beneﬁcial effects of exercise in
patients with type 2 diabetes. In contrast to their expectations,
the results have shown that daily supplementation with vitamin
C and vitamin A for 4 weeks not only failed to improve the
insulin responsiveness but also decreased the expression of
ROS-sensitive transcriptional regulators, molecular mediators
of ROS defense (SOD 1 and 2, glutathione peroxidase).90
Thus, antioxidant supplement seems to have blocked endoge-
nous defenses rather than counteract the oxidant stress. This
emphasizes that exogeneous antioxidants need to block the
oxidant pathways without suppressing the endogenous antiox-
idant mechanisms.
The Nrf2 pathway is a negative regulator of inﬂamma-
tion according to the hierarchical oxidative stress model.8,9
Sulforaphane is a potent Nrf2 agonist, which is found in high
amounts in broccoli. Studies using human bronchial epithelial
cells conﬁrm that sulforaphane is effective in suppressing the
proinﬂammatory effects of diesel exhaust particles. It effec-
tively upregulates GSTM1 and blocks interleukin (IL)-8,
granulocyte-macrophage colony-stimulating factor (GM-
CSF), IL-1b production in the bronchial epithelial cells.91
Quercetin is a ﬂavonoid molecule found in a variety of
foods especially in apples and has antioxidant and anti-
inﬂammatory properties.92,93 Quercetin was shown to inhibit
proinﬂammatory cytokines and NO production through MAP
kinases and NF-kB pathway in lipopolysaccharide-stimulated
cells.93 Dietary intake of the soy isoﬂavone genistein was
associated with reduced allergic respiratory symptoms.94 In
animal models, genistein blocks allergen-induced airway in-
ﬂammation in ex vivo allergen-challenged guinea-pig bronchi
and lung specimens. Intratracheal instillation of genistein was
shown to reduce leukotriene and histamine levels.89 In sup-
port of these studies, asthma patients with high dietary gen-
istein consumption had less severe airﬂow obstruction than
those who consume little or no genistein.95
a-Lipoic acid is a nonenzymatic antioxidant and is pres-
ent in various foods and oral supplements. In an animal model,
a-lipoic acid treatment was associated with reduced airway
hyperresponsiveness, lower eosinophil counts, and IL-4
and IL-5 concentrations in BAL, improved pathology of the
lungs, and lower intracellular ROS and NF-kB DNA-binding
activity.96 Recently, Metha et al84 reported that choline and
a-lipoic acid treatment reduces ROS production and isopros-
tanes in BAL ﬂuid and thus suppresses oxidative stress.
Another food derivative, epigallocatechin 3 gallate,
a component of polyphenols derived from green tea, was
shown to be a potent inhibitor of IL-1b–induced MUC5AC
gene expression and MUC5AC secretion97 and has antioxi-
dant activity.98
SOD Mimetics
Transgenic mice that over express SOD have decreased
allergen induced physiologic changes in the airway compared
with controls.49 A number of SOD mimetics have been
developed possessing antioxidant properties in vivo99,100
and their beneﬁts have been identiﬁed in animal models.101
SOD mimetic (SODm) M40403 was shown to decrease the
physiological and histopathological lung abnormalities in the
ovalbumin model of allergic asthma reaction in sensitized
guinea pigs.101
Molecules Affecting Glutathione System
Ebselen, a nontoxic, seleno-organic drug, is an effective
reductant of hydroperoxides. It mimics glutathione peroxidase.
In animal models, it inhibits airway inﬂammation by reducing
neutrophil chemotaxis and chemokine expression.102
Resveratrol, a phytoalexin found in seeds of grapes, has
antioxidant and anti-inﬂammatory effects. It effectively inhibits
oxidative damage and scavenges free radicals. It induces
glutathione (GSH) synthesis and attenuates GSH depletion in
lung epithelial cells during the oxidative stress.103 Most studies
done thus far on resveratrol was performed on either animal
models or in vitro systems. In a recent study, resveratrol
blocked the release of both IL-8 and GM-CSF from alveolar
macrophages of patients with COPD both at basal state and
after stimulation with IL-1b and cigarette smoke.104 Resvera-
trol was shown to decrease IL-1 and tumor necrosis factor-a105
expression and reduce iNOS expression, COX-2 messenger
RNA, and production of IL-8 and GM-CSF106 in human lung
epithelial cells More studies need be done to understand how
resveratrol ﬁts into inﬂammatory pathways in the development
of novel therapies for the treatment of asthma.
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Nanomaterials
Nanotechnology provides fullerene nanomaterials,
which are soccer ball–shaped carbon cages that are among
the most potent free radical scavengers due to their capacity
to absorb electrons. They have been shown to inhibit IgE-
mediated human mast cell and peripheral blood basophils
mediator release in vitro.107 The clinical applications of these
products in humans have not yet been investigated.
CURRENT ASTHMA THERAPY AND
OXIDATIVE STRESS
Anti-inﬂammatory therapy using corticosteroids
remains to be the mainstay of treatment and is emphasized
in all guidelines.108,109 The efﬁcacy of current asthma therapy
in preventing the effects of oxidative stress is not yet clear and
sometimes controversial.
Corticosteroids may have direct effects on oxidative
stress by decreasing the number and/or activity of cells
involved in ROS.110 Even though some studies have sug-
gested that they may also increase the antioxidant enzyme
levels,111 this observation was not supported by others.112
Clinical studies have produced some challenging results
as well. In a recent study, it was shown that patients with
asthma who were well controlled with inhaled corticosteroids
and long-acting b2 agonists had higher lipid peroxide levels
compared with healthy controls.113 Similarly, intranasal cor-
ticosteroids failed to prevent the oxidative burden produced
by intranasal ragweed allergen challenge.114 It is also impor-
tant to remember that ROS may inactivate histone deacety-
lase-2, an essential factor for corticosteroid inhibition of the
inﬂammatory response.115
CONCLUSION
Asthma is associated with a strong oxidant stress that is
a result of both increased oxidant forces and decreased
antioxidant capacity. Even though modulation of this system
offers great promise in the treatment of inﬂammatory
diseases, such as asthma, more work is needed to discover
a clinically useful compound.
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